Antiphospholipid syndrome

Laboratory detection, mechanisms of action and treatment

A. Tripodi, P. G. de Groot, V. Pengo

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.

Original languageEnglish
Pages (from-to)110-122
Number of pages13
JournalJournal of Internal Medicine
Volume270
Issue number2
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Antiphospholipid Syndrome
Blood Vessels
Pregnancy Complications
Therapeutics
Lupus Coagulation Inhibitor
Cardiolipins
Glycoproteins
Medicine
Antibodies

Keywords

  • Arterial thromboembolism
  • Foetal loss
  • Laboratory testing
  • Pregnancy complications
  • Venous thromboembolism

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Antiphospholipid syndrome : Laboratory detection, mechanisms of action and treatment. / Tripodi, A.; de Groot, P. G.; Pengo, V.

In: Journal of Internal Medicine, Vol. 270, No. 2, 08.2011, p. 110-122.

Research output: Contribution to journalArticle

@article{50babe7a9f794605a811cb84191ffdba,
title = "Antiphospholipid syndrome: Laboratory detection, mechanisms of action and treatment",
abstract = "The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.",
keywords = "Arterial thromboembolism, Foetal loss, Laboratory testing, Pregnancy complications, Venous thromboembolism",
author = "A. Tripodi and {de Groot}, {P. G.} and V. Pengo",
year = "2011",
month = "8",
doi = "10.1111/j.1365-2796.2011.02362.x",
language = "English",
volume = "270",
pages = "110--122",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Antiphospholipid syndrome

T2 - Laboratory detection, mechanisms of action and treatment

AU - Tripodi, A.

AU - de Groot, P. G.

AU - Pengo, V.

PY - 2011/8

Y1 - 2011/8

N2 - The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.

AB - The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or β 2-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events.

KW - Arterial thromboembolism

KW - Foetal loss

KW - Laboratory testing

KW - Pregnancy complications

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=79959382588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959382588&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2796.2011.02362.x

DO - 10.1111/j.1365-2796.2011.02362.x

M3 - Article

VL - 270

SP - 110

EP - 122

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 2

ER -